Biotechnology company Immuron has announced positive results for its anti-diarrhoea vaccine in targeting the main bacteria responsible for sickness that besets international travellers and personnel stationed overseas such as the military.
The United States Naval Research Centre (NMRC) has completed analysis of cows vaccinated against Campylobacter and Entereotoxigenic Escherichia coli, noting a ‘robust immune response’.
The cows’ colostrum or milk contained high levels of specific immunoglobulins against the target antigens, and antibodies capable of inhibiting the two bacteria strains.
Two human controlled infection-model clinical trials are now scheduled for next year, with the NMRC pursuing regulatory applications.
A contract manufacturer is making the drug product for the clinical evaluation which will be carried out by the US Department of Defence.
Immuiron came to the attention of USD authorities with approval for the sale of its Travelan product, an over the counter immune supplement that can be taken to reduce the risk of diarrhoea and reduce the symptoms of minor gastrointestinal disorders.
Travelan helps to support a healthy digestive system by supporting the gut’s immune defences.
Subscribe to our free @AuManufacturing newsletter here.